# Elizabeth Roper

> Elizabeth Roper is a seed investor at Epidarex Capital backing Biotechnology and Therapeutics. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Epidarex Capital](https://shizune.co/investors/profile/epidarex-capital)
- Location: Edinburgh, United Kingdom
- Total investments: 6
- Last investment: Apr 2022
- Lead investor: 83%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/elizabeth-roper-1758202

Elizabeth Roper is a seed investor at Epidarex Capital in Edinburgh focused on Biotechnology and Therapeutics. Elizabeth Roper is based out of Edinburgh, Scotland and is the Managing Partner of Epidarex Capital. Elizabeth previously worked at Chroma Therapeutics as a Director of Business Development. Elizabeth Roper attended the University College Cork.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 67% |
| Therapeutics | 3 | 50% |
| Health Care | 2 | 33% |
| Medical | 1 | 17% |
| Pharmaceutical | 1 | 17% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 50% |
| Series A | 2 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Kynos Therapeutics | Kynos Therapeutics develops KMO inhibitors across key indications in inflammation, immunity, and metabolism. | $8.5M | Seed | Apr 07, 2022 |  |
| Dunad Therapeutics | Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies. | $24M | Series A | Nov 02, 2021 |  |
| Macomics | Macomics is an immuno-oncology company. Macomics focus on the development of novel, first-in-class immunotherapies designed to modulate macrophages, increasing the body’s immune defence against tumours. | $5.9M | Seed | Jul 29, 2021 |  |
| Dunad Therapeutics | Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies. |  | Seed | Mar 23, 2021 |  |
| Macomics | Macomics is an immuno-oncology company. Macomics focus on the development of novel, first-in-class immunotherapies designed to modulate macrophages, increasing the body’s immune defence against tumours. | $4M | Seed | Jul 14, 2020 |  |
| AdoRx Therapeutics | AdoRx Therapeutics is pursuing the discovery of new therapeutics for cancer based on modulation of the adenosine pathway. High levels of adenosine in the tumour microenvironment enable cancer to evade the immune system. AdoRx’s lead programs are focused on the design of “fit for purpose” adenosine receptor antagonists that will overcome the effectsof high adenosine levels. AdoRx Therapeutics is a UK-based drug discovery company and backed by investment from Epidarex Capital and Sixth Element Capital. The AdoRx leadership team have discovered in excess of 25 clinical candidates and have greater than 60 years combined experience of drug discovery in biotech and pharma. | $10M | Series A | Jun 21, 2018 |  |

6 of 6 investments shown.

## Co-investors
- [IP Group](https://shizune.co/investors/profile/ip-group-plc) — VC Fund, 2 deals together
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund, 2 deals together
- [BioGeneration Ventures](https://shizune.co/investors/profile/biogeneration-ventures) — VC Fund, 1 deal together
- [Caribou Property](https://shizune.co/investors/profile/caribou-property) — VC Fund, 1 deal together
- [Novartis](https://shizune.co/investors/profile/novartis) — VC Fund, 1 deal together
- [Scottish Investment Bank](https://shizune.co/investors/profile/scottish-investment-bank) — VC Fund, 1 deal together

## About Epidarex Capital

VC Fund · Bethesda, United States

Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.

5 contacts available at Epidarex Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Elizabeth Roper | Partner | https://shizune.co/investors/profile/elizabeth-roper |
| Peter Finan | Partner | https://shizune.co/investors/profile/peter-finan |
| Terri Burke | Venture Partner | https://shizune.co/investors/profile/terri-burke |
| Kyparissia Sirinakis | Founder & Managing Partner | https://shizune.co/investors/profile/kyparissia-sirinakis |
| Sinclair Dunlop | Managing Partner | https://shizune.co/investors/profile/sinclair-dunlop |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Elizabeth Roper invest in?

Elizabeth Roper invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Seed and Series A stage. Most of the 6 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Elizabeth Roper last invest?

The most recent investment recorded for Elizabeth Roper closed in Apr 2022. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co